Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.radonc.2017.12.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidermal growth factor receptor exon 20 insertion mutations: are we getting closer to solving the puzzle?
Transl Lung Cancer Res
November 2024
Division of Medical Oncology, Duke Cancer Institute, Durham, NC, USA.
Advanced lung adenocarcinoma with 19-del mutation transforms into squamous cell carcinoma after tyrosine kinase inhibitor treatment.
World J Clin Cases
November 2024
Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China.
In this editorial we comment on the article by Ji . We focus specifically on the EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment and the development of drug resistance to EGFR-TKIs.
View Article and Find Full Text PDFIs the transverse colon the new right?-similarities in EGFR drug response and prognosis.
J Gastrointest Oncol
October 2024
Gastrointestinal Cancer Unit, Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain.
Rearranging development makes a slippery slope: a commentary on 'Carnivorous Nepenthes pitcher plants combine common developmental processes to make a complex epidermal trapping surface'.
Ann Bot
November 2024
Sainsbury Laboratory, Bateman Street, Cambridge, CB2 1LR, UK.
Consolidation osimertinib for unresectable stage III epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer: redefining standard care.
Transl Lung Cancer Res
October 2024
Division of Oncology, Department of Medicine, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!